Paper · 6352007
Serial immune function testing to predict clinical disease relapse in patients with solid tumors.
Braun DP and 1 other. Cancer Immunol Immunother, 1983. Cited by 12 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Serial immune function testing to predict clinical disease relapse in patients with solid tumors. Papers, record 6352007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6352007
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Serial immune function testing to predict clinical disease relapse in patients with solid tumors.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunity, Cellular | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Immunologic Techniques | |
| Leukocyte Count | |
| Lymphocyte Activation | |
| T-Lymphocytes | |
| Time Factors |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 658,104 | Failure of lymphocyte microcytotoxicity to distinguish relapsers from non-relapsers in melanoma patients receiving post-surgical adjuvant chemotherapy. | Eur J Cancer (1965) | 1978 | https://conductscience.org/library/papers/658104 | PubMed |
| 2 | 200,722 | Immunobiology of primary intracranial tumors. Part 3: Microcytotoxicity assays of specific immune responses of brain tumor patients. | J Neurosurg | 1977 | https://conductscience.org/library/papers/200722 | PubMed |
| 3 | 304,759 | Immunologic reactivity in patients with primary operable breast cancer. | Cancer | 1978 | https://conductscience.org/library/papers/304759 | PubMed |
| 4 | 972,084 | Lymphopenia and metastatic breast cancer patients with and without radiation therapy. | Int J Radiat Oncol Biol Phys | 1976 | https://conductscience.org/library/papers/972084 | PubMed |
| 5 | 752,865 | Specific active immunochemotherapy in lung cancer: a survival study. | Recent Results Cancer Res | 1978 | https://conductscience.org/library/papers/752865 | PubMed |
| 6 | 6,603,261 | Serial immune testing in surgically resected lung cancer patients. | Cancer Immunol Immunother | 1983 | https://conductscience.org/library/papers/6603261 | PubMed |
| 7 | 1,078,826 | Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor. | J Clin Invest | 1975 | https://conductscience.org/library/papers/1078826 | PubMed |
| 8 | 310,169 | Depression of 'high affinity' T-cell rosettes indicative of recurrent carcinoma. | Surg Forum | 1977 | https://conductscience.org/library/papers/310169 | PubMed |
| 9 | 423,328 | Immune response in bladder cancer patients. | J Urol | 1979 | https://conductscience.org/library/papers/423328 | PubMed |
| 10 | 6,447,164 | Autologous mixed lymphocyte reaction in patients with Hodgkin's disease. Evidence for a T cell defect. | J Clin Invest | 1980 | https://conductscience.org/library/papers/6447164 | PubMed |
1 to 10 of 51
See all 51 referencesCited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41,488,054 | Bridging ancient wisdom and modern technology: an AI and multi-omics framework for three causes tailored treatment in personalized medicine. | Front Mol Biosci | 2025 | https://conductscience.org/library/papers/41488054 | PubMed |
| 11,401,315 | Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. | Br J Cancer | 2001 | https://conductscience.org/library/papers/11401315 | PubMed |
| 7,981,084 | Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. | Br J Cancer | 1994 | https://conductscience.org/library/papers/7981084 | PubMed |
| 3,719,596 | Immune reactivity in cattle with ocular squamous cell carcinoma after intralesional BCG immunotherapy. | Cancer Immunol Immunother | 1986 | https://conductscience.org/library/papers/3719596 | PubMed |
| 2,784,716 | Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guérin. | Cancer Immunol Immunother | 1989 | https://conductscience.org/library/papers/2784716 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6352007
GET https://conductscience.org/api/papers/v1/6352007/references?page=2